Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.

AIM To explore the feasibility and activity of a histology-based induction combination chemotherapy for elderly patients with clinical stage III non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Patients aged ≥70 years with stage IIIA and IIIB lung squamous cell carcinoma (SCC) or adenocarcinoma were treated with three cycles of carboplatin and gemcitabine or pemetrexed, respectively, followed by definitive radiotherapy or surgery. The primary endpoint was the overall response rate (ORR) following induction. RESULTS Twenty-seven patients, with a median age of 74 years (range=70-80 years) were treated for adenocarcinoma in 14 (52%) and SCC in 13 (48%), clinical stage IIIA in eight (30%) and IIIB in 19 (70%). Grade 3 or 4 toxicity was reported for five patients (18.5%). The ORR was 46% in 12 (partial responses) out of 26 assessable patients. CONCLUSION Histology-based induction combination chemotherapy is active and feasible in elderly patients with stage III NSCLC.

[1]  R. Blanco,et al.  A review of the management of elderly patients with non-small-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  K. Asami.  First-line Treatment in Elderly Patients with Advanced Non-small Cell Lung Cancer , 2015 .

[3]  G. Banna,et al.  A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer , 2013, Medical Oncology.

[4]  B. Milleron,et al.  Concurrent chemoradiation for elderly patients with locally advanced non-small-cell lung cancer: still a controversial issue , 2012 .

[5]  B. Milleron,et al.  Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial , 2011, The Lancet.

[6]  S. Novello,et al.  Maintenance therapy in NSCLC: why? To whom? Which agent? , 2011, Journal of experimental & clinical cancer research : CR.

[7]  Xianglin L. Du,et al.  Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  D. Lacombe,et al.  EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[10]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[12]  M. Hasegawa,et al.  High-dose radiation therapy for elderly patients with inoperable or unresectable non-small cell lung cancer. , 2001, Lung cancer.

[13]  R. A’Hern.  Sample size tables for exact single‐stage phase II designs , 2001, Statistics in medicine.

[14]  R. Simon,et al.  Confidence intervals for reporting results of clinical trials. , 1986, Annals of internal medicine.

[15]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[16]  D.,et al.  Regression Models and Life-Tables , 2022 .